Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 16:30:51 13/02/2026 GMT			5-day change	1st Jan Change
125.14 ^CHF	+1.08%		+4.32%	+14.18%

02-13	Sector Update: Health Care Stocks Advance Late Afternoon	MT
02-13	Sector Update: Health Care Stocks Higher Friday Afternoon	MT

SciNeuro, Novartis sign $1.7 billion licensing deal to develop Alzheimer's drugs

Published on 01/12/2026 at 02:40 pm GMT

Reuters

Latest news about Novartis AG

02-13	Sector Update: Health Care Stocks Advance Late Afternoon	MT
02-13	Sector Update: Health Care Stocks Higher Friday Afternoon	MT
02-13	European Equities Mixed in Friday Trading; Spain's January CPI Declines	MT
02-13	Swiss Market Index Recovers as Inflation Holds Steady; Leclanché Tumbles	MT
02-13	Sector Update: Health Care Stocks Edge Higher Premarket Friday	MT
02-13	Novartis Says Vanrafia Late-Stage Data Support Slowing of Kidney Function Decline in IgA Nephropathy Patients	MT
02-13	European Midday Briefing : AI Nerves Linger Ahead of U.S. Inflation Data	DJ
02-13	Novartis Announces Final Results from the Phase III ALIGN Study	CI
02-13	PRESS DIGEST-Wall Street Journal - February 13	RE
02-13	Novartis' Vanrafia Slows Kidney Function Decline in Late-stage Study	MT
02-13	Novartis Says Vanrafia Drug Slows Kidney Function Decline	DJ
02-13	Novartis Vanrafia® Phase III data support slowing of kidney function decline	RE
02-13	Novartis Vanrafia(R) Phase III data support slowing of kidney function decline in patients with IgA nephropathy	DJ
02-12	Central Garden & Pet Appoints Kay M. Schwichtenberg as New Director, Effective March 1, 2026	CI
02-12	Oryzon Genomics, S.A. Announces Chief Medical Officer For CNS Programs Changes	CI

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).

Employees

75,267

Sector

Pharmaceuticals

Calendar

03-02 - TD Cowen Health Care Conference

More about the company